Oral verapamil inhibits platelet thrombus formation in humans

L. L-Lacoste, J.Y.T. Lam, Joe Hung, D. Waters

    Research output: Contribution to journalArticlepeer-review

    38 Citations (Scopus)


    Background Calcium antagonists such as verapamil are potent coronary and systemic vasodilators that are used in the treatment of coronary disease. They have also been shown to inhibit platelet aggregation in vitro, but whether they have beneficial antithrombotic effects in humans is unclear, and whether they can potentiate the antithrombotic effects of aspirin is unknown. Methods and Results Platelet thrombus formation and whole blood platelet aggregation were measured in 18 stable coronary patients on three separate occasions: at baseline when receiving no active medications, after 7 days of receiving oral verapamil SR (240 mg/d), and after 7 days of receiving a combination of oral verapamil SR and aspirin (325 mg/d). Thrombus formation on porcine aortic media that were placed into cylindrical flow chambers and exposed to flowing antecubital venous blood for 3 minutes was assessed morphometrically at a shear rate of 2546 s(-1), which is typical of arterial flow at sites of stenoses. Thrombus formation under basal conditions was 7.0+/-1.6 mu m(2), and this was decreased to 3.1+/-0.5 mu m(2) (P
    Original languageEnglish
    Pages (from-to)630-634
    Publication statusPublished - 1994


    Dive into the research topics of 'Oral verapamil inhibits platelet thrombus formation in humans'. Together they form a unique fingerprint.

    Cite this